ECSP056023A - Métodos para aislar la forma cristalina I de la 5-azacitidina - Google Patents

Métodos para aislar la forma cristalina I de la 5-azacitidina

Info

Publication number: ECSP056023A
Authority: EC; Ecuador
Prior art keywords: azacitidine; methods; crystalline form; isolating crystalline; provides
Prior art date: 2003-03-17

Application number

EC2005006023A

Other languages

English (en)

Spanish (es)

Inventor

Ionescu Dumitru

Blumbergs Peter

L Silvey Gary

Original Assignee

Pharmion Corp

Ash Stevens Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-03-17

Filing date

2005-09-16

Publication date

2006-01-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32987551&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP056023(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-09-16 Application filed by Pharmion Corp, Ash Stevens Inc filed Critical Pharmion Corp

2006-01-27 Publication of ECSP056023A publication Critical patent/ECSP056023A/es

Links

NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 title abstract 4
238000000034 method Methods 0.000 title abstract 3
229960002756 azacitidine Drugs 0.000 abstract 1
239000013078 crystal Substances 0.000 abstract 1
239000003937 drug carrier Substances 0.000 abstract 1
239000012212 insulator Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000008024 pharmaceutical diluent Substances 0.000 abstract 1
239000000546 pharmaceutical excipient Substances 0.000 abstract 1
239000011877 solvent mixture Substances 0.000 abstract 1
238000005728 strengthening Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/12—Triazine radicals

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Hematology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Saccharide Compounds (AREA)
Medicinal Preparation (AREA)

EC2005006023A 2003-03-17 2005-09-16 Métodos para aislar la forma cristalina I de la 5-azacitidina ECSP056023A (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US10/390,530 US6943249B2 (en)	2003-03-17	2003-03-17	Methods for isolating crystalline Form I of 5-azacytidine

Publications (1)

Publication Number	Publication Date
ECSP056023A true ECSP056023A (es)	2006-01-27

Family

ID=32987551

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EC2005006023A ECSP056023A (es)	2003-03-17	2005-09-16	Métodos para aislar la forma cristalina I de la 5-azacitidina

Country Status (16)

Country	Link
US (5)	US6943249B2 (pl)
EP (3)	EP2266965A1 (pl)
JP (1)	JP4792550B2 (pl)
AU (2)	AU2004222274B2 (pl)
BR (1)	BRPI0408506A (pl)
CA (1)	CA2518973A1 (pl)
CY (2)	CY1114213T1 (pl)
DK (2)	DK2181988T3 (pl)
EC (1)	ECSP056023A (pl)
ES (2)	ES2575535T3 (pl)
HU (1)	HUE028268T2 (pl)
MX (1)	MXPA05009969A (pl)
PL (2)	PL1608634T3 (pl)
PT (2)	PT1608634E (pl)
SI (2)	SI1608634T1 (pl)
WO (1)	WO2004082822A2 (pl)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL8902490A (nl) *	1989-10-06	1991-05-01	Leonardus Mathijs Marie Nevels	Werkwijze voor het reinigen van rookgassen.
DE60116318T2 (de) *	2001-10-08	2006-08-31	Alcatel	Verfahren zur Lastverteilung zwischen mehreren gemeinsamen Betriebsmitteln in einem Kommunikationsnetzwerk und Netzwerk zur Anwendung des Verfahrens
US8404717B2 (en) *	2002-10-15	2013-03-26	Celgene Corporation	Methods of treating myelodysplastic syndromes using lenalidomide
US11116782B2 (en)	2002-10-15	2021-09-14	Celgene Corporation	Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404716B2 (en)	2002-10-15	2013-03-26	Celgene Corporation	Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US6887855B2 (en) *	2003-03-17	2005-05-03	Pharmion Corporation	Forms of 5-azacytidine
US7038038B2 (en) *	2003-03-17	2006-05-02	Pharmion Corporation	Synthesis of 5-azacytidine
US6943249B2 (en) *	2003-03-17	2005-09-13	Ash Stevens, Inc.	Methods for isolating crystalline Form I of 5-azacytidine
US7192781B2 (en) *	2004-04-13	2007-03-20	Pharmion Corporation	Methods for stabilizing 5-azacytidine in plasma
WO2008044041A1 (en)	2006-10-12	2008-04-17	Astex Therapeutics Limited	Pharmaceutical combinations
WO2008044045A1 (en)	2006-10-12	2008-04-17	Astex Therapeutics Limited	Pharmaceutical combinations
US7759481B2 (en) *	2007-01-11	2010-07-20	Ivax Corporation	Solid state forms of 5-azacytidine and processes for preparation thereof
EP2176279A4 (en) *	2007-08-02	2012-01-11	Chemagis Ltd	HIGH-PURITY, STABLE AZACYTIDINE AND METHODS OF PREPARATION
BRPI0817234A2 (pt) *	2007-09-26	2014-09-30	Sinai School Medicine	Análogos de azacitidina e seus usos
CA2742252A1 (en) *	2007-11-01	2009-05-07	Celgene Corporation	Cytidine analogs for treatment of myelodysplastic syndromes
HUE055911T2 (hu)	2008-05-15	2021-12-28	Celgene Corp	Citidin-analógokat tartalmazó orális készítmények, és eljárások azok alkalmazására
WO2010014883A2 (en)	2008-08-01	2010-02-04	Dr. Reddy's Laboratories Ltd.	Azacitidine process and polymorphs
AU2009279461B2 (en) *	2008-08-08	2014-01-23	Scinopharm Taiwan, Ltd.	Process for making 5-azacytosine nucleosides and their derivatives
WO2010129211A2 (en) *	2009-04-27	2010-11-11	Dr. Reddy's Laboratories Ltd.	Preparation of decitabine
US20110042247A1 (en) *	2009-06-25	2011-02-24	Chandrasekhar Kocherlakota	Formulations of azacitidine and its derivatives
JP2014503597A (ja)	2011-01-31	2014-02-13	セルジーンコーポレイション	シチジンアナログの医薬組成物及びその使用方法
JP6289361B2 (ja)	2011-03-31	2018-03-07	セルジーンインターナショナルサルル	５−アザシチジンの合成
WO2013022872A1 (en)	2011-08-10	2013-02-14	Celgene Corporation	Gene methylation biomarkers and methods of use thereof
CN104114182A (zh)	2011-09-23	2014-10-22	细胞基因公司	罗米地辛和5-阿扎胞苷在治疗淋巴瘤中的应用
CN104039330A (zh)	2011-09-26	2014-09-10	细胞基因公司	化疗耐药性的癌症的联合治疗
US8980850B2 (en)	2011-11-03	2015-03-17	Millennium Pharmaceuticals, Inc.	Administration of a NEDD8-activating enzyme inhibitor and hypomethylating agent
WO2013080221A2 (en) *	2011-12-01	2013-06-06	Hetero Research Foundation	Process for alvimopan
US9669048B2 (en) *	2012-10-25	2017-06-06	Fresenius Kabi Oncology Limited	Stable pharmaceutical composition of 5-aza-2′-deoxycitidine
US9765108B2 (en)	2012-11-19	2017-09-19	Shilpa Medicare Limited	Formulation of 5-azacytidine
WO2014076616A2 (en) *	2012-11-19	2014-05-22	Shilpa Medicare Limited	Formulations of 5-azacytidine
WO2014160698A1 (en)	2013-03-26	2014-10-02	Celgene Corporation	SOLID FORMS COMPRISING 4-AMINO-I-β-D-RIBOFURANOSYL-1,3,5-TRIAZIN-2(1H)-ONE AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
CN103450303A (zh) *	2013-09-04	2013-12-18	重庆泰濠制药有限公司	阿扎胞苷晶型a、阿扎胞苷晶型b及其制备方法
US10034872B2 (en)	2014-08-22	2018-07-31	Celgene Corporation	Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
US20160095925A1 (en) *	2014-10-01	2016-04-07	Cadila Healthcare Limited	Stable formulation of azacitidine or salts thereof and their process for preparation
MX381582B (es)	2015-10-15	2025-03-12	Celgene Corp	Terapia de combinacion para el tratamiento de neoplasias malignas.
DK3362066T3 (da)	2015-10-15	2021-11-22	Les Laboratoires Servier Sas	Kombinationsterapi til behandling af maligniteter
EP3527226A4 (en) *	2016-10-17	2020-06-17	Daiichi Sankyo Company, Limited	COMBINATION THERAPY PROCEDURE WITH MDM2 INHIBITOR AND DNA METHYL TRANSFERASE INHIBITOR
CN109988207B (zh) *	2017-12-29	2022-01-04	江苏豪森药业集团有限公司	阿扎胞苷晶型的制备方法
US10632211B2 (en)	2018-06-11	2020-04-28	The Regents Of The University Of California	Demethylation to treat eye disease
CN110642901A (zh) *	2019-11-11	2020-01-03	扬子江药业集团有限公司	阿扎胞苷甲醇化物及其制备方法和药物组合物、用途
US20240262857A1 (en) *	2021-05-27	2024-08-08	Emory University	Novel universal anti-rna virus agents
WO2026068588A1 (en)	2024-09-30	2026-04-02	Synthon B.V.	Improved azacitidine composition

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1050899A (pl) *	1963-12-22
CH527207A (de)	1968-05-08	1972-08-31	Ceskoslovenska Akademie Ved	Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
CH507969A (de)	1968-11-12	1971-05-31	Ceskoslovenska Akademie Ved	Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
DE2012888C3 (de)	1970-03-14	1981-04-02	Schering Ag, 1000 Berlin Und 4619 Bergkamen	Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden
FR2123632A6 (en)	1971-01-26	1972-09-15	Ceskoslovenska Akademie Ved	Prepn of 5-azacytosines and 5-azacytidines - from bis trimethylsilyl-5-azacytosine
DE2122991C2 (de) *	1971-05-04	1982-06-09	Schering Ag, 1000 Berlin Und 4619 Bergkamen	Verfahren zur Herstellung von Cytosin- und 6-Azacytosinnucleosiden
DE2508312A1 (de) *	1975-02-24	1976-09-02	Schering Ag	Neues verfahren zur herstellung von nucleosiden
DE2757365A1 (de) *	1977-12-20	1979-06-21	Schering Ag	Neues verfahren zur herstellung von nucleosiden
US5700640A (en)	1994-09-16	1997-12-23	Basf Aktiengesellschaft	Inducers of gamma globin gene expression and screening assays therefor
US5539209A (en)	1994-10-17	1996-07-23	Trojan Technologies Inc.	Method of cleaning fouling materials from a radiation module
TW513409B (en)	1996-06-07	2002-12-11	Eisai Co Ltd	Polymorphs of donepezil hydrochloride
JPH1053576A (ja) *	1996-06-07	1998-02-24	Eisai Co Ltd	塩酸ドネペジルの多形結晶およびその製造法
AU738170B2 (en)	1996-10-16	2001-09-13	Icn Pharmaceuticals, Inc.	Monocyclic L-nucleosides, analogs and uses thereof
DE60009695T2 (de) *	1999-06-03	2004-09-23	Eisai Co., Ltd.	Kristalline cabapenemderivate und pharmazeutische zubereitungen zur injektion
MXPA02000314A (es)	1999-07-09	2004-06-22	Boehringer Ingelheim Pharma	Proceso novedoso para la sintesis de compuestos de urea substituidos con heteroarilo.
SK9742002A3 (en)	2000-01-07	2003-02-04	Transform Pharmaceuticals Inc	High-throughput formation, identification, and analysis of diverse solid-forms
HUP0302929A3 (en)	2000-09-07	2004-10-28	Kaneka Corp	Methods for crystallization of hydroxycarboxylic acids
PT1574512E (pt) *	2001-03-01	2008-03-05	Abbott Lab	Formas polimórficas e outras formas cristalinas de cis-ftc
AU2003278904A1 (en)	2002-09-24	2004-04-19	Kornis Pharmaceuticals, Incorporated	1, 3, 5-triazines for treatment of viral diseases
US7189740B2 (en)	2002-10-15	2007-03-13	Celgene Corporation	Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
CA2503150A1 (en)	2002-10-31	2004-05-21	Supergen, Inc.	Pharmaceutical formulations targeting specific regions of the gastrointestinal tract
CN1802352A (zh)	2003-02-03	2006-07-12	特瓦制药工业有限公司	制备左乙拉西坦的方法
US7038038B2 (en)	2003-03-17	2006-05-02	Pharmion Corporation	Synthesis of 5-azacytidine
US6943249B2 (en)	2003-03-17	2005-09-13	Ash Stevens, Inc.	Methods for isolating crystalline Form I of 5-azacytidine
US6887855B2 (en)	2003-03-17	2005-05-03	Pharmion Corporation	Forms of 5-azacytidine
US6877855B2 (en)	2003-07-08	2005-04-12	Dave Ng	Spectacles with peripheral lens support
JP2007504131A (ja)	2003-08-29	2007-03-01	エートンファーマインコーポレーティッド	癌の組み合わせ処置法
US7192781B2 (en)	2004-04-13	2007-03-20	Pharmion Corporation	Methods for stabilizing 5-azacytidine in plasma
US20060069060A1 (en)	2004-09-27	2006-03-30	Sanjeev Redkar	Salts of decitabine
US20060063735A1 (en)	2004-09-17	2006-03-23	Supergen, Inc.	Salts of 5-azacytidine
US20060128654A1 (en)	2004-12-10	2006-06-15	Chunlin Tang	Pharmaceutical formulation of cytidine analogs and derivatives
US20080057086A1 (en)	2006-09-01	2008-03-06	Pharmion Corporation	Colon-targeted oral formulations of cytidine analogs
US7759481B2 (en)	2007-01-11	2010-07-20	Ivax Corporation	Solid state forms of 5-azacytidine and processes for preparation thereof
US20080182806A1 (en)	2007-01-25	2008-07-31	Nevada Cancer Institute	Use of acetylated or esterificated azacytidine, decitabine, or other nucleoside analogs as oral agents for the treatment of tumors or other dysplastic syndromes sensitive to hypomethylating agents
EP2176279A4 (en)	2007-08-02	2012-01-11	Chemagis Ltd	HIGH-PURITY, STABLE AZACYTIDINE AND METHODS OF PREPARATION
EP2048151A1 (en)	2007-10-10	2009-04-15	Cilag AG	Method for producing nucleosides by direct glycosylation of the nucleoside base
CA2742252A1 (en)	2007-11-01	2009-05-07	Celgene Corporation	Cytidine analogs for treatment of myelodysplastic syndromes
HUE055911T2 (hu)	2008-05-15	2021-12-28	Celgene Corp	Citidin-analógokat tartalmazó orális készítmények, és eljárások azok alkalmazására
WO2010014883A2 (en)	2008-08-01	2010-02-04	Dr. Reddy's Laboratories Ltd.	Azacitidine process and polymorphs
EP2324042B1 (en)	2008-08-06	2012-11-28	Sicor, Inc.	Process for preparing azacytidine intermediate
AU2009279461B2 (en)	2008-08-08	2014-01-23	Scinopharm Taiwan, Ltd.	Process for making 5-azacytosine nucleosides and their derivatives
US20110042247A1 (en)	2009-06-25	2011-02-24	Chandrasekhar Kocherlakota	Formulations of azacitidine and its derivatives
WO2011014541A1 (en)	2009-07-30	2011-02-03	Eagle Pharmaceuticals, Inc.	Stable formulations of azacitidine
IT1399195B1 (it)	2010-03-30	2013-04-11	Chemi Spa	Processo per la sintesi di azacitidina e decitabina

2003
- 2003-03-17 US US10/390,530 patent/US6943249B2/en not_active Expired - Lifetime
2004
- 2004-03-16 CA CA002518973A patent/CA2518973A1/en not_active Withdrawn
- 2004-03-16 PT PT47210786T patent/PT1608634E/pt unknown
- 2004-03-16 WO PCT/US2004/007896 patent/WO2004082822A2/en not_active Ceased
- 2004-03-16 BR BRPI0408506-0A patent/BRPI0408506A/pt not_active IP Right Cessation
- 2004-03-16 PL PL04721078T patent/PL1608634T3/pl unknown
- 2004-03-16 EP EP10178178A patent/EP2266965A1/en not_active Withdrawn
- 2004-03-16 EP EP04721078.6A patent/EP1608634B1/en not_active Expired - Lifetime
- 2004-03-16 SI SI200432065T patent/SI1608634T1/sl unknown
- 2004-03-16 ES ES10151392.7T patent/ES2575535T3/es not_active Expired - Lifetime
- 2004-03-16 AU AU2004222274A patent/AU2004222274B2/en not_active Expired
- 2004-03-16 JP JP2006507211A patent/JP4792550B2/ja not_active Expired - Lifetime
- 2004-03-16 MX MXPA05009969A patent/MXPA05009969A/es active IP Right Grant
- 2004-03-16 ES ES04721078T patent/ES2425474T3/es not_active Expired - Lifetime
- 2004-03-16 DK DK10151392.7T patent/DK2181988T3/en active
- 2004-03-16 PL PL10151392.7T patent/PL2181988T3/pl unknown
- 2004-03-16 SI SI200432323A patent/SI2181988T1/sl unknown
- 2004-03-16 DK DK04721078.6T patent/DK1608634T3/da active
- 2004-03-16 EP EP10151392.7A patent/EP2181988B1/en not_active Revoked
- 2004-03-16 HU HUE10151392A patent/HUE028268T2/en unknown
- 2004-03-16 PT PT101513927T patent/PT2181988E/pt unknown
2005
- 2005-08-05 US US11/198,550 patent/US7700770B2/en not_active Expired - Lifetime
- 2005-09-16 EC EC2005006023A patent/ECSP056023A/es unknown
2010
- 2010-03-22 US US12/729,116 patent/US8211862B2/en not_active Expired - Fee Related
- 2010-11-03 AU AU2010241198A patent/AU2010241198B2/en not_active Expired
2012
- 2012-06-05 US US13/489,307 patent/US8481715B2/en not_active Expired - Fee Related
2013
- 2013-06-07 US US13/913,163 patent/US8975392B2/en not_active Expired - Lifetime
- 2013-08-14 CY CY20131100700T patent/CY1114213T1/el unknown
2016
- 2016-05-31 CY CY20161100474T patent/CY1117639T1/el unknown

Also Published As

Publication number	Publication date
ES2425474T3 (es)	2013-10-15
PL2181988T3 (pl)	2016-11-30
US6943249B2 (en)	2005-09-13
US8975392B2 (en)	2015-03-10
US8481715B2 (en)	2013-07-09
JP2006523210A (ja)	2006-10-12
SI1608634T1 (sl)	2013-09-30
PL1608634T3 (pl)	2013-10-31
CA2518973A1 (en)	2004-09-30
EP1608634B1 (en)	2013-05-22
US20130274459A1 (en)	2013-10-17
US20120245342A1 (en)	2012-09-27
AU2004222274A1 (en)	2004-09-30
EP1608634A2 (en)	2005-12-28
AU2004222274B2 (en)	2010-11-04
AU2010241198A1 (en)	2010-11-25
DK2181988T3 (en)	2016-06-06
BRPI0408506A (pt)	2006-03-14
MXPA05009969A (es)	2006-02-17
ES2575535T3 (es)	2016-06-29
US20040186284A1 (en)	2004-09-23
DK1608634T3 (da)	2013-08-12
US7700770B2 (en)	2010-04-20
JP4792550B2 (ja)	2011-10-12
WO2004082822A2 (en)	2004-09-30
EP2181988A1 (en)	2010-05-05
US20100292180A1 (en)	2010-11-18
SI2181988T1 (sl)	2016-09-30
PT2181988E (pt)	2016-06-15
US20050272675A1 (en)	2005-12-08
US8211862B2 (en)	2012-07-03
EP1608634A4 (en)	2006-03-15
WO2004082822A3 (en)	2005-07-07
EP2266965A1 (en)	2010-12-29
CY1117639T1 (el)	2017-04-26
HUE028268T2 (en)	2016-12-28
PT1608634E (pt)	2013-08-27
CY1114213T1 (el)	2016-08-31
AU2010241198B2 (en)	2012-05-10
EP2181988B1 (en)	2016-05-11

Publication	Publication Date	Title
CY1117639T1 (el)	2017-04-26	Φαρμακευτικες συνθεσεις βασιζομενες επι κρυσταλλικης μορφης i της 5-αζακυτιδινης
CO5680428A2 (es)	2006-09-29	Antagonistas del receptor de trombina
AR053412A1 (es)	2007-05-09	Compuestos inhibidores de la interaccion entre mdm2 y p53, un metodo de preparadcion, composicion farmaceutica y uso del compuesto para fabricar medicamentos
CL2019002919A1 (es)	2020-01-17	Compuestos inhibidores vmat2 y composiciones relacionadas.
CR9664A (es)	2009-07-07	Inhibidores de histona deacetilasa
CO6210825A2 (es)	2010-10-20	Derivado de heterocicliden-n-(aril)acetamina
UY28187A1 (es)	2004-09-30	Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
CR8402A (es)	2008-09-10	Indazol-o-glucosidos sustitutos
GT200400133AA (es)	2007-07-10	Derivados de pirrolo[3,4-c] pirazol, activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden. (solicitud fraccionaria no. 1, derivada de la patente no. pi-2004-0133).
ECSP066406A (es)	2006-09-18	Derivados de pirimidina para el tratamiento del crecimiento celular anormal
AR082499A1 (es)	2012-12-12	Compuestos utiles para trastornos del sistema nervioso, inflamatorios, estomacales y como analgesicos
AR067316A1 (es)	2009-10-07	Moleculas secuestradoras de oxigeno, articulos que las contienen y metodos para su uso
UY28674A1 (es)	2005-07-29	Inhibidores heterociclil amino de 11-beta-hidroxiesteroide deshidrogenasa tipo 1
CR10937A (es)	2009-11-20	Inhibidores de cinasa mapk/erk
CR11036A (es)	2009-10-06	Derivados y composiciones de isoindol 4' -o- sustituidos, composiciones que las comprenden y metodos de uso de los mismos
UY27716A1 (es)	2003-04-30	Derivados de nitrosodifenilamina y composiciones farmacéuticas que los comprenden como medicamentos que se pueden utilizar en el tratamiento de patologías que se caracterizan por estrés oxidativo.
AR053336A1 (es)	2007-05-02	Formas cristalinas de un compuesto de bifenilo
TW200722422A (en)	2007-06-16	Heterocyclic compound and organic electroluminescent device using the same
BRPI0409105A (pt)	2006-04-25	análogos de quinobenzoxazina substituìdos
UY26564A1 (es)	2001-03-16	Inhibidores del factor xa con aril - amidinas y sus derivados, y composiciones farmacéuticas que contienen los mismos
PA8582101A1 (es)	2004-04-23	Indoles sustituidos en posicion 2,4
UY27410A1 (es)	2003-03-31	Formas novedosas crudas cristalinas
AR027360A1 (es)	2003-03-26	Composicion farmaceutica
AR042910A1 (es)	2005-07-06	Compuestos de pirazolopirimidina y procedimiento para preparar el mismo y composiciones farmaceuticas que los contienen
UY28821A1 (es)	2005-10-31	Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos.